Qiang Shi

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Senior Staff Fellow

NCTR primary UAMS

Also affiliated: Jiangxi University of Traditional Chinese Medicine (2025); Jiangnan University (2011–2013); Zhejiang Chinese Medical University (2008); Jiangsu University (2025); University of Science and Technology of China (2026); Dalhousie University (2018); United States Food and Drug Administration (2009–2025); Zhejiang Sci-Tech University (2023); Center for Drug Evaluation and Research (2020); North China University of Science and Technology (2022); Nanchang University (2022–2025); Johns Hopkins University (2024); Sun Yat-sen University (2016–2019); China Three Gorges University (2022); Hunan University (2002); Pfizer (United States) (2012–2014); Shanghai Jiao Tong University (2022); Capital Medical University (2017); Dalian Medical University (2012); Liaocheng University (2022); Chinese Academy of Sciences (2022–2026); Shanghai University of Electric Power (2008); Fudan University (2016–2024); Johns Hopkins Medicine (2024); China-Japan Friendship Hospital (2017); Sir Run Run Shaw Hospital (2019); Tianjin Medical University General Hospital (2015); Chinese PLA General Hospital (2023); Soochow University (2022); Inner Mongolia Electric Power (China) (2023); Shanghai Stomatological Hospital (2023); Chongqing Bureau of Geology and Minerals Exploration (2021–2024); Changchun Institute of Applied Chemistry (2022–2026); Dalian University (2012); Fudan University Shanghai Cancer Center (2023); Hefei National Center for Physical Sciences at Nanoscale (2016); Xinjiang Industry Technical College (2022); Affiliated Hospital of Taishan Medical University (2022–2025); Chongqing Maternal and Child Health Hospital (2023); Analysis and Testing Centre (2013); Shanghai Open University (2024); Xinjiang Institute of Engineering (2022); PAREXEL International (United States) (2012); Zhongshan Hospital (2016–2024); First Automotive Works (China) (2023); Changchun University of Chinese Medicine (2023); Chinese Academy of Forestry (2010–2011); Institute of Software (2009); The First Affiliated Hospital, Sun Yat-sen University (2016–2019); Jining First People's Hospital (2023); Research Institute of Wood Industry (2010–2011); First Hospital of China Medical University (2009–2011); Changchun Institute of Technology (2022); Zhejiang Pharmaceutical College (2008); Shanghai Sixth People's Hospital (2022); Obstetrics and Gynecology Hospital of Fudan University (2023); Beijing Friendship Hospital (2017); Pfizer (China) (2012–2014); Food and Drug Administration (2008–2014); State Key Laboratory of Food Science and Technology (2022–2024); State Key Laboratory of Polymer Physics and Chemistry (2022); Sichuan Research Center of New Materials (2017); South China Institute of Collaborative Innovation (2023); Center for Life Sciences (2023–2024); Shandong First Medical University (2022–2025); University of Chinese Academy of Sciences (2022); Dezhou University (2010–2013); Hebei University (2005); Northwest Normal University (2023–2024); Zhejiang University (2006–2019); Southeast University (2025); Shaanxi Normal University (2016–2018); China Medical University (2009–2011); Tsinghua University (2023–2024)

Staff Researcher

36 h-index 207 pubs 10,804 cited

Upstream record may be merged OpenAlex, the source of these figures, lists 76 institutions in 4 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Qiang Shi's research investigates molecular mechanisms underlying cellular processes, with a recent focus on ubiquitination and its role in protein regulation and disease. His work has explored the structural and mechanistic basis of deubiquitination by specific enzymes, such as USP16, and the mechanisms of ubiquitination mediated by factors like yeast Bre1-Rad6 and its human homolog RNF20/RNF40-hRAD6A. Shi has also examined the function of proteins like Synovial sarcoma X breakpoint 1 in recognizing ubiquitinated nucleosomes.

Beyond ubiquitination, his research has touched upon other cellular pathways relevant to health. This includes investigating the ferroptosis mechanism in the context of Alzheimer's disease and exploring how combinations of compounds, such as nicotinamide mononucleotide and lycopene, can prevent cognitive impairment and oxidative damage in aging models. Shi has also contributed to the study of drug-induced liver injury through co-culture systems involving primary hepatocytes and nonparenchymal liver cells in liver-chip models.

With an h-index of 35 and over 10,670 citations across more than 205 publications, Shi is recognized as a highly cited researcher. He collaborates with colleagues at the National Center for Toxicological Research, including Laura K. Schnackenberg, Katy S Papineau, and Lijun Ren.

Metrics

h-index: 36
Publications: 207
Citations: 10,804

Selected Publications

Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)

Toxicology Letters 2 citations DOI OpenAlex
Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids (2025)

Biochemistry and Biophysics Reports 4 citations DOI OpenAlex
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)

Biochemical and Biophysical Research Communications 3 citations DOI OpenAlex
Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development (2025)

ALTEX 1 citation DOI OpenAlex
New Alternative Methods in Drug Safety Assessment (2023)

DOI OpenAlex